CFO4Life Group LLC lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,429 shares of the biopharmaceutical company’s stock after buying an additional 317 shares during the period. Gilead Sciences makes up approximately 0.7% of CFO4Life Group LLC’s holdings, making the stock its 16th largest position. CFO4Life Group LLC’s holdings in Gilead Sciences were worth $738,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also made changes to their positions in the company. Harel Insurance Investments & Financial Services Ltd. lifted its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after purchasing an additional 1,400 shares during the period. Penserra Capital Management LLC lifted its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 144 shares during the period. Webster Bank N. A. lifted its position in Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after purchasing an additional 624 shares during the period. American Beacon Advisors Inc. acquired a new stake in Gilead Sciences in the first quarter valued at about $143,000. Finally, Welch Group LLC lifted its position in Gilead Sciences by 9.7% in the first quarter. Welch Group LLC now owns 2,857 shares of the biopharmaceutical company’s stock valued at $194,000 after purchasing an additional 252 shares during the period. Institutional investors and hedge funds own 74.28% of the company’s stock.
A number of brokerages recently commented on GILD. ValuEngine upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. TheStreet upgraded shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Zacks Investment Research downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, September 11th. Vetr downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective for the company. in a research report on Monday, September 4th. Finally, Morgan Stanley restated an “equal weight” rating and issued a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $85.68.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.40 billion. During the same quarter in the prior year, the business posted $2.75 EPS. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date is Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.77%. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.
In related news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now directly owns 113,237 shares in the company, valued at approximately $8,945,723. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the transaction, the executive vice president now owns 62,715 shares in the company, valued at $5,217,260.85. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 358,486 shares of company stock worth $29,637,678. 1.30% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “CFO4Life Group LLC Acquires 317 Shares of Gilead Sciences, Inc. (GILD)” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://sportsperspectives.com/2017/11/02/cfo4life-group-llc-acquires-317-shares-of-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.